Small Molecules to Complex Biologics: Mastering Bioanalytical Workflows Using High Resolution Mass Spectrometry (HRMS)

Why It Matters

HRMS platforms that handle both small molecules and complex biologics streamline bioanalysis, reducing method development time and cost for pharmaceutical R&D and regulated labs.

Key Takeaways

• HRMS quantifies small polar metabolites like succinic acid with high sensitivity
• ZenoTOF 7600+ measures in‑vivo drug‑to‑antibody ratios for ADCs
• Single‑platform workflow handles both small molecules and complex biologics
• Eliminates sensitivity bottlenecks in low‑abundance bioanalysis
• Enables rapid method development for regulated LC‑MS labs

Pulse Analysis

High‑resolution mass spectrometry is rapidly becoming the backbone of modern bioanalysis, offering the precision required for both low‑molecular‑weight metabolites and large‑scale biologics. The ZenoTOF 7600+ exemplifies this shift by delivering sub‑ppm mass accuracy and enhanced ion transmission, which translates into superior sensitivity for challenging analytes such as highly hydrophilic organic acids. For pharmaceutical companies, this means more reliable pharmacokinetic data and faster decision‑making during early‑stage drug discovery.

Beyond sensitivity, the platform’s versatility addresses a critical bottleneck: the need for multiple instruments to cover diverse therapeutic modalities. By consolidating small‑molecule quantitation and antibody‑drug conjugate (ADC) characterization onto a single system, labs can reduce capital expenditures and simplify validation pathways. The webinar’s case studies—succinic acid quantitation and trastuzumab‑MMAE DAR profiling—illustrate how a unified workflow can maintain regulatory compliance while accelerating turnaround times for complex matrices.

For senior scientists and lab managers, adopting HRMS technology signals a strategic move toward future‑proof analytics. The ability to swiftly develop robust methods across a spectrum of analytes supports agile R&D pipelines and aligns with increasing regulatory expectations for data integrity. As the biotech landscape continues to evolve, platforms like the ZenoTOF 7600+ will likely become the standard for high‑throughput, high‑confidence bioanalytical testing, driving both scientific insight and commercial competitiveness.